REMYELIKIDS
What it found
No result yet.
What was tested
Treatment tested
- MRI without injection of contrast product
What it measured
Main measures
MTR-based individual indices
1 day
Myelin repairThinking and memory
Other measures (1)
indices of cortical remyelination
6 months
Myelin repair
Who could take part
Relapsing MS · 12 to 18
Inclusion Criteria for patients : * age between 12 years old and 18 years old * RR-MS defined by 2017 McDonald criteria * no relapse the last 4 weeks * no methylprednisolone or prednisolone the last 4 weeks. * affiliated to the social security system * signature of the consent by the 2 holders of parental authority Inclusion Criteria for Volunteers: * age between 12 years old and 18 years old * absence of any neurological * signature of the consent by the 2 holders of parental authority Exclusion Criteria for both groups: * Parental rejection * Contre-indication of brain MRI: pace maker, tatoo of the face, claustrophobia…. * Pregnancy, copper intrauterine device
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
Multiple sclerosis (MS) in children, a rare disease, follows a relapsing remitting course with a shorter interval between the first 2 clinical events and higher annualized relapse rate as compared with MS in adults. Residual deficits following clinical events are less frequent. The vast majority of children and adolescents with MS are thought to have a greater potential for myelin repair than adults. However convincing data in the literature to support this hypothesis are lacking, because until now no imaging technique has been validated to measure remyelination in vivo.
Loading reviews and guidelines…
Related trials
- INFLANET
Not a drug-phase study · Recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Im…
Not a drug-phase study · Running, not recruiting
Still running
- Effect of Alemtuzumab on Microglial Activation Positron E…
Phase 1 / Phase 2 · Withdrawn
Stopped early
- 9-month Study to Assess the Efficacy of Ofatumumab on Mic…
Phase 3 · Completed
Results posted, no main test reported
- MS_SV2
Phase 2 · Completed
No result found
History
Started
Aug 2022
Main results due
Sept 2026
Finished
Sept 2026
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error